logo-loader
viewBod Australia Ltd

Bod Australia imports first medical cannabis product to Australia

Phase I trial to commence in May 2018 with completion scheduled before the end of 2018.

a woman holding a cannabis leaf
Potential to add another source to the company’s growing revenue profile

Bod Australia Ltd (ASX:BDA) has imported Swiss herbal extracts company Linnea SA’s proprietary cannabidiol (CBD) extract powder, ECs315, for use in its upcoming phase I clinical trial.

The powder will be incorporated into a proprietary sublingual wafer delivery solution (WaferiX®) developed through Bod’s pharmaceutical partner iX Biopharma (SGX:42C).

READ: Bod Australia secures supply deal for medicinal cannabis extracts

Following the formulation of the wafer, Bod will commence its phase I clinical trial to determine the safety, tolerability and pharmacokinetics of the wafer, which will be administered to healthy volunteers.

Bod is expecting the trial to officially commence by May 2018.

Medical cannabis market to reach US$55.8 billion by 2025

Upon completion of the trial, Bod will have exclusive access to a proprietary product that includes a globally unique extract, as well as a patent protected delivery method.

The company can either distribute it or licence it to major pharma companies globally – giving access to the estimated global medical cannabis market of about US$55.8 billion by 2025.

Sales in Australia through special access scheme

In addition to the CBD extract powder, Bod expects receipt of Linnea’s proprietary 5% CBD in MCT oil in country imminently.

Both products will be made available to approved prescribers and patients under the Therapeutic Goods Administration’s (TGA) Special Access Scheme.

Sales of these products will potentially add another revenue stream to the company’s growing revenue profile (nutritional and skin care products).

READ: Bod Australia taps into new revenue source through agreement with Manuka Pharma

Bod chief executive officer Jo Patterson said: “This is another major achievement for the company and we are excited to have received the necessary materials to finalise our sublingual wafer with iX Biopharma.

“Upon completion of the formulation, the company will begin its phase I clinical trial and following, begin to develop a range of products that leverage the uniqueness of this product, along with licence opportunities that may arise.”

Quick facts: Bod Australia Ltd

Price: 0.22 AUD

ASX:BDA
Market: ASX
Market Cap: $20.1 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Admedus Ltd 'in good shape' with minimal disruption to supply chain as it...

Admedus Ltd's (ASX:AHZ) Wayne Paterson caught up with Proactive's Andrew Scott to discuss the steps and precautions the firm's taking in the wake of the recent virus outbreak. The company's just announced the hospital discharge of the first patient following its clinical surgical aortic valve...

16 hours, 52 minutes ago

2 min read